Lithostat

(Acetohydroxamic Acid)

Phase 2Small molecule

MMission Pharmacal

Lithostat is one of 2 small molecule programs targeting MDR-TB. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

MDR-TBNot yet recruiting

MDR-TBPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in MDR-TB

#DrugCompanyPhaseTrials

Sirturo

WWim Janssens

Phase 3

1 2

Lithostat

MMission Pharmacal

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

MDR-TB

NCT07393438

Clinical

Trials by Indication[1]

Gut Microbiome1 trial

Manipulating the Gut Microbiome Study

Terminated·NNicholas Ah Mew·Phase 1/2·NCT03181828·4 enrolled

MDR-TB1 trial

Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT07393438·120 enrolled

Regulatory

FDA Approval Timeline[4]

May 31, 1983

LITHOSTAT

NDA NDA018749

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Acetohydroxamic Acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acetohydroxamic Acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acetohydroxamic Acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018749). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Mission Pharmacal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMission Pharmacal

Lithostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Gut Microbiome1 trial

MDR-TB1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News